Vepalimomab Biosimilar – Anti-AOC3, VAP1 mAb – Research Grade

Vepalimomab Biosimilar – Anti-AOC3, VAP1 mAb – Research Grade

Vepalimomab Biosimilar – Anti-AOC3, VAP1 mAb – Research Grade: A Novel Antibody Targeting AOC3 for Therapeutic Applications

Introduction

Vepalimomab Biosimilar is a research grade monoclonal antibody (mAb) targeting the enzyme amine oxidase copper-containing 3 (AOC3), also known as vascular adhesion protein-1 (VAP-1). This novel antibody has shown promising results in preclinical studies and has the potential to be a valuable therapeutic tool for various diseases.

Structure of Vepalimomab Biosimilar

Vepalimomab Biosimilar is a humanized IgG1 monoclonal antibody consisting of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for the specific binding of Vepalimomab Biosimilar to its target, AOC3.

Mechanism of Action

Vepalimomab Biosimilar works by binding to AOC3, a cell surface enzyme that plays a crucial role in leukocyte trafficking and inflammation. This binding leads to the inhibition of AOC3 activity, thereby reducing leukocyte recruitment and inflammation. In addition, Vepalimomab Biosimilar also has the potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC), where immune cells are activated to attack and destroy cells expressing AOC3 on their surface.

Therapeutic Applications

Research has shown that AOC3 is involved in various diseases, making it a potential therapeutic target for a wide range of conditions. Vepalimomab Biosimilar has shown promising results in preclinical studies for the treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has also been studied for its potential in reducing leukocyte recruitment in cancer and transplant rejection.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation in the joints. AOC3 has been found to play a crucial role in the pathogenesis of RA by promoting leukocyte recruitment and inflammation. In preclinical studies, Vepalimomab Biosimilar has shown to reduce joint inflammation and destruction, making it a promising therapeutic option for RA.

Psoriasis

Psoriasis is a chronic skin disorder characterized by red, scaly patches on the skin. AOC3 has been found to be overexpressed in psoriatic skin lesions, and its inhibition has shown to reduce inflammation in preclinical studies. Vepalimomab Biosimilar has the potential to be a targeted therapy for psoriasis by inhibiting AOC3 activity and reducing inflammation in the skin.

Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD) is a group of chronic inflammatory disorders of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis. AOC3 has been found to be upregulated in the inflamed gut tissue of IBD patients, and its inhibition has shown to reduce inflammation and improve disease symptoms in preclinical studies. Vepalimomab Biosimilar has the potential to be a targeted therapy for IBD by inhibiting AOC3 and reducing gut inflammation.

Cancer and Transplant Rejection

AOC3 has also been found to play a role in cancer and transplant rejection by promoting leukocyte recruitment and inflammation in these